SF3B1 and myelodysplastic syndrome: The European LeukemiaNet (ELN) expert panel recognizes mutations in ASXL1, EZH2 (histone modifiers), SRSF2, and SF3B1 (splicing factors) as adverse MDS/AML risk factors [5].